Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations is critical. The advent of next-generation sequencing (NGS) has led to an exponential increase in the number of variants detected in tumor testing, posing a challenge for clinical cancer genetics professionals seeking to confidently discern clinically relevant mutations that can guide patient care decisions.

Join Dr. Umadevi Thirumurthi, Associate Director of Global Product Management for Oncology at QIAGEN Digital Insights as she discusses how the Human Somatic Mutation Database (HSMD), an expert-curated somatic variant database, can enhance your clinical NGS workflow.